Gilead Science Korea
Gilead Sciences Korea is a subsidiary of Gilead Sciences Inc., established in 2011, dedicated to developing and supplying innovative medicines in the fields of virology, HIV, hepatitis, oncology, and inflammation. The company aims to realize a healthier world for all by advancing global health, sustainability, and social contribution through partnerships and community engagement.
Industries
Nr. of Employees
medium (51-250)
Gilead Science Korea
Products
Epclusa (sofosbuvir/velpatasvir)
Oral regimen for treatment of chronic hepatitis C virus infection across multiple genotypes in adults and pediatric patients 12 years and older (≥30 kg).
Vosevi (sofosbuvir/velpatasvir/voxilaprevir)
Oral regimen indicated for certain adults with chronic hepatitis C virus infection, including patients with prior NS5A inhibitor exposure as specified in local labeling.
Harvoni (ledipasvir/sofosbuvir)
Oral regimen for treatment of chronic hepatitis C virus infection in adults and pediatric patients 12–17 years for certain genotypes.
Sovaldi (sofosbuvir)
Oral antiviral indicated in combination regimens for treatment of chronic hepatitis C virus infection in adults and certain pediatric populations.
Vemlidy (tenofovir alafenamide fumarate)
Oral therapy indicated for treatment of chronic hepatitis B in adults.
Viread (tenofovir disoproxil fumarate)
Oral antiviral indicated for treatment of chronic hepatitis B and used in combination regimens for HIV-1 infection.
Epclusa (sofosbuvir/velpatasvir)
Oral regimen for treatment of chronic hepatitis C virus infection across multiple genotypes in adults and pediatric patients 12 years and older (≥30 kg).
Vosevi (sofosbuvir/velpatasvir/voxilaprevir)
Oral regimen indicated for certain adults with chronic hepatitis C virus infection, including patients with prior NS5A inhibitor exposure as specified in local labeling.
Harvoni (ledipasvir/sofosbuvir)
Oral regimen for treatment of chronic hepatitis C virus infection in adults and pediatric patients 12–17 years for certain genotypes.
Sovaldi (sofosbuvir)
Oral antiviral indicated in combination regimens for treatment of chronic hepatitis C virus infection in adults and certain pediatric populations.
Vemlidy (tenofovir alafenamide fumarate)
Oral therapy indicated for treatment of chronic hepatitis B in adults.
Viread (tenofovir disoproxil fumarate)
Oral antiviral indicated for treatment of chronic hepatitis B and used in combination regimens for HIV-1 infection.
Services
Grant funding and donation program for eligible non‑profit organizations, with online application, eligibility checks, and review timelines.
Patient support services including local reimbursement support center for program-specific therapies and patient solutions teams to improve access.
Online portal and contact channel for healthcare professional inquiries about product information and medical questions.
Designated channels for adverse event and safety reporting to the company's safety team.
Grant funding and donation program for eligible non‑profit organizations, with online application, eligibility checks, and review timelines.
Patient support services including local reimbursement support center for program-specific therapies and patient solutions teams to improve access.
Online portal and contact channel for healthcare professional inquiries about product information and medical questions.
Designated channels for adverse event and safety reporting to the company's safety team.
Expertise Areas
- Antiviral drug development (HIV, HBV, HCV)
- Oncology drug development and cell therapy collaboration
- Clinical development and therapeutic program management
- Access and licensing strategies for low- and middle-income countries
Key Technologies
- Liposomal injectable formulation
- Oral combination antiretroviral therapies
- Cell therapy platforms (collaborative development)
- Voluntary licensing and manufacturing partnerships
News & Updates
The label of Truvada® will be changed on March 13, 2025, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of AmBisome® will be changed on August 14, 2024, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of Vemlidy® will be changed on October 20, 2023, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of Veklury® will be changed on June 5, 2023, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of Sovaldi® will be changed on January 12, 2023, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of Truvada® will be changed on March 13, 2025, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of AmBisome® will be changed on August 14, 2024, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of Vemlidy® will be changed on October 20, 2023, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of Veklury® will be changed on June 5, 2023, following the re-examination results of the Ministry of Food and Drug Safety, Korea.
The label of Sovaldi® will be changed on January 12, 2023, following the re-examination results of the Ministry of Food and Drug Safety, Korea.